-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

92 IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies

Program: Oral and Poster Abstracts
Type: Oral
Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: CAR-T Cell Therapies for Lymphomas and ALL: New Strategies and Toxicities
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Research
Saturday, December 7, 2024: 9:45 AM

Yugang Guo, PhD1,2,3*, Qianwen Xu, Master1*, Lei Xue, Master1*, Erlin Chen, Master1*, Xuhan Zhang, MD1*, Chonglin Liu, Master2*, Min Gao, PhD2,3*, Youjia Li, PhD2*, Jingjing Ren, PhD, MD2*, Karthik Sathiyanadan, PhD2*, Li Tang, PhD4,5*, He Huang, MD6,7,8,9,10*, Yongxian Hu7,9,11,12* and Xingbing Wang13*

1Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
2Leman Biotech Co., Ltd., Shenzhen, China
3Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University; State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China
4Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
5Institute of Materials Science & Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
6Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
7The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8Bone marrow transplantation department, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
9Institute of Hematology, Zhejiang University, Hangzhou, China
10Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
11Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, China
12Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
13Department of Hematology, The First Affiliated Hospital of USCT (Anhui Provincial Hospital), Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

Context:

Despite the undeniable success of CAR-T therapy in treating hematological malignancies, persistent challenges such as ineffectiveness and relapse after remission are observed, often due to CAR-T cell exhaustion and dysfunction. To address these issues, metabolically armored CAR-T cells expressing IL-10 have demonstrated significant improvements in the proliferation and persistence of CAR-T cells in vivo. These engineered cells exhibit remarkable resistance to exhaustion and elicit stem-like memory responses in animal models, resulting in robust tumor eradication and durable protection. To further evaluate both efficacy and safety, we have initiated an open-label, single-arm, investigator-initiated phase I trial (NCT06277011) of IL-10 expressing CD19 CAR-T cells, denoted as Meta10-19, targeting patients with relapsed or refractory B-cell hematological malignancies.

Objective:

The primary objective of this phase I trial is to assess the safety and tolerability of Meta10-19 among patients diagnosed with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and B-cell acute lymphoblastic leukemia (B-ALL). Secondary goals encompass investigating pharmacokinetics and gauging initial efficacy outcomes.

Methods:

From February 2023 to July 2024, we enrolled and treated a total of 20 eligible patients with elapsed or refractory B-cell hematological malignancies, including 10 patients with DLBCL and 10 patients with B-ALL. Patients received a single infusion of Meta10-19 across multiple dose level (DL) cohorts from 2.0×104 cells/kg to 2.0×105 cells/kg. The administration followed a standard lymphodepletion regimen involving 30 mg/m2/day fludarabine for 3 days, and 300 mg/m2/day cyclophosphamide for 3 days. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were graded according to Lee 2014 and ASTCT 2019 guidelines, respectively. Adverse events (AEs) were assessed based on CTCAE 5.0 criteria.

Results:

As of July 16, 2024, Meta10-19 had been successfully infused into 20 eligible patients, who subsequently underwent comprehensive safety and preliminary efficacy evaluations. The median age of the cohort was 50 years (range 17-65). CAR-T cells reached their expansion peak at about 12 days for both DLBCL and B-ALL patients. Remarkably, the complete response (CR) rate for all 20 patients was 100% (20/20), sustained at 100% for 3 months (19/19), and maintained at 94.11% at 6 months (16/17) post-treatment, which is much higher than commercial products (approximately 50% at 6 months post-treatment). Notably, 5 patients have been surviving over 12 months, with the longest observed remission duration to date being 17 months. Treatment-related adverse events, predominantly neutropenia, thrombocytopenia, and anemia, were manageable and effectively resolved with standard and supportive care.

Summary:

This first-in-human trial of Meta10-19 has demonstrated encouraging preliminary efficacy and a manageable safety profile. Notably, Meta10-19 exhibited a significantly higher CR rate compared to commercial products. Additionally, it provided substantial long-term survival benefits for infused cancer patients, especially at 6 months post-treatment. Ongoing investigations with larger patient cohorts and extended follow-up periods aim to provide further insight into the efficacy and safety parameters.

Disclosures: Ren: Leman Biotech Co., Ltd.: Current Employment.

OffLabel Disclosure: Meta10-19 is a IL-10 expressing CD19 CAR-T cell injection.

*signifies non-member of ASH